Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All azvudine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 74% Improvement Relative Risk Ventilation 91% ICU admission 75% Progression 57% Azvudine for COVID-19  Shen et al.  LATE TREATMENT Is late treatment with azvudine beneficial for COVID-19? PSM retrospective 452 patients in China Lower mortality (p=0.04) and progression (p=0.048) with azvudine c19early.org Shen et al., medRxiv, January 2023 Favors azvudine Favors control

Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study

Shen et al., medRxiv, doi:10.1101/2023.01.23.23284899
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Azvudine for COVID-19
39th treatment shown to reduce risk in May 2023
 
*, now known with p = 0.000076 from 13 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
PSM retrospective 900 hospitalized COVID-19 patients in China showing lower risk of disease progression and death with azvudine treatment.
risk of death, 74.0% lower, HR 0.26, p = 0.04, treatment 3 of 226 (1.3%), control 10 of 226 (4.4%), NNT 32, propensity score matching, Cox proportional hazards.
risk of mechanical ventilation, 90.9% lower, RR 0.09, p = 0.06, treatment 0 of 226 (0.0%), control 5 of 226 (2.2%), NNT 45, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), propensity score matching.
risk of ICU admission, 75.0% lower, RR 0.25, p = 0.37, treatment 1 of 226 (0.4%), control 4 of 226 (1.8%), NNT 75, propensity score matching.
risk of progression, 57.0% lower, HR 0.43, p = 0.048, treatment 8 of 226 (3.5%), control 17 of 226 (7.5%), NNT 25, all-cause death, intensive care unit admission, initiation of invasive mechanical ventilation, and need for high-flow oxygen therapy, propensity score matching, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shen et al., 23 Jan 2023, retrospective, China, preprint, 12 authors. Contact: dengguangtong@outlook.com, chenxiangck@126.com, shenmx1988@csu.edu.cn, zengflorachn@hotmail.com.
This PaperAzvudineAll
Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study
Minxue Shen, Chenggen Xiao, Yuming Sun, Daishi Li, Ping Wu, Liping Jin, Qingrong Wu, Yating Dian, Yu Meng, Furong Zeng, Xiang Chen, Guangtong Deng
doi:10.1101/2023.01.23.23284899
Current guidelines prioritize the use of the Azvudine in coronavirus disease 2019 (COVID-19) patients. However, the clinical effectiveness of Azvudine in real-world studies was lacking, despite the clinical trials showed shorter time of nucleic acid negative conversion. To evaluate the clinical effectiveness following Azvudine treatment in hospitalized COVID-19 patients, we identified 1505 hospitalized COVID-19 patients during the study period, with a follow-up of up to 29 days. After exclusions and propensity score matching, we included 226 Azvudine recipients and 226 matched controls. The lower crude incidence rate of composite disease progression outcome (4.21 vs. 10.39 per 1000 person-days, P=0.041) and all-cause mortality (1.57 vs. 6.00 per 1000 person-days, P=0.027) were observed among Azvudine recipients compared with matched controls. The incidence rates of initiation of invasive mechanical ventilation were also statistically different between the groups according to the log-rank tests (P=0.020). Azvudine treatment was associated with significantly lower risks of composite disease progression outcome (hazard ratio [HR]: 0.43; 95% confidence interval [CI]: 0.18 to 0.99) and all-cause death (HR: 0.26; 95% CI: 0.07 to 0.94) compared with matched controls. Subgroup analyses indicated robustness of the point estimates of HRs (ranged from 0.14 to 0.84). Notably, male Azvudine recipients had a stronger effectiveness than female recipients with respect to both composite outcome and all-cause death. These findings suggest that Azvudine treatment showed substantial clinical benefits in hospitalized COVID-19 patients, and should be considered for use in this population of patients.
CONFLICT OF INTERESTS The authors declare no conflicts of interest that pertain to this work. CONTRIBUTIONS Conception and design: Guangtong, Xiang Chen, Furong Zeng, and Minxue Shen. Acquisition of data: Furong Zeng, Chenggen Xiao, Yuming Sun, Daishi Li, Ping Wu. Interpretation of data, statistical analysis and manuscript writing: Guangtong Deng, Furong Zeng, and Minxue Shen.
References
Amani, Amani, Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19 : a rapid review and meta-analysis, J Med Virol, doi:10.1002/jmv.28441
Austin, Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations, Biom J, doi:10.1002/bimj.200810488
Chang, 4'-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives, Acc Chem Res, doi:10.1021/acs.accounts.1c00697
Cheema, Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis, J Med Virol, doi:10.1002/jmv.28471
Lieber, SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model, Nat Commun, doi:10.1038/s41467-022-32045-1
Murakami, Therapeutic advances in COVID-19, Nat Rev Nephrol, doi:10.1038/s41581-022-00642-4
Ren, A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study, Adv Sci (Weinh), doi:10.1002/advs.202001435
Ye, China approves first homegrown COVID antiviral, Nature, doi:10.1038/d41586-022-02050-x
Yu, Chang, Azvudine, FNC): a promising clinical candidate for COVID-19 treatment, Signal Transduct Target Ther, doi:10.1038/s41392-020-00351-z
Yu, Chang, The first Chinese oral anti-COVID-19 drug Azvudine launched, Innovation (Camb), doi:10.1016/j.xinn.2022.100321
Zhang, Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients, Signal Transduct Target Ther, doi:10.1038/s41392-021-00835-6
Zheng, Efficacy and safety of Paxlovid for COVID-19:a meta-analysis, J Infect, doi:10.1016/j.jinf.2022.09.027
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit